<DOC>
	<DOCNO>NCT02995954</DOCNO>
	<brief_summary>The introduction fix combination ACEi+CCB ( Fixed ) significantly increase patient compliance adherence therapy . At moment , however , data suggest good control once-daily fix ( Fixed ) free dos separate administration combination therapy hypertensive . In population 39 consecutive outpatient patient refer departmental Hypertension clinic University Hospital Salerno Medical School first diagnosis arterial hypertension , investigator test hypothesis Fixed achieve good control blood pressure Free combination . Patients randomize either strategy 3 month patient underwent clinical assessment evaluate antihypertensive effect .</brief_summary>
	<brief_title>Fixed vs Free Dose ACEi/CCB Combination Therapy</brief_title>
	<detailed_description>Study Population Our study include 100 patient referred Hypertension Clinic Salerno Medical School Hospital Salerno , first diagnosis arterial hypertension absence previous treatment . At time enrollment visit , patient sign consent anonymous participation , compliance regulation good clinical practice privacy . Study participants 18-75 year old essential hypertension ( define accord ESH / ESC 2013 guideline ) . Patients exclude patient secondary hypertension , malignant hypertension , CRF ( chronic renal failure ) , oncological condition cirrhosis . Patients also exclude patient medical surgical disorder alter absorption , distribution , metabolism excretion drug treatment . The study protocol approve competent University Hospital Ethical Committee . Study Design Patients randomize either fix dose free dose combination therapy , Perindopril ( 5 10 mg ) Amlodipine ( 5 10 mg ) 2:1 randomization design base power analysis . Doses decide accord anthropometric , clinical , biochemical instrumental dos experience medical staff . The Fixed group receive one single tablet contain Perindopril/Amlodipine appropriate dose . The Free group , receive Perindopril Amlodipine separate tablet appropriate dose . Groups match age , sex , BMI , systolic BP ( SBP ) diastolic BP ( DBP ) . At baseline follow-up investigator evaluate clinical ( weight , height , BMI , heart rate , BP ) biochemical parameter ( blood glucose , serum cholesterol , LDL , HDL , triglyceride , blood urea nitrogen , creatinine , creatinine clearance ) , well Electrocardiogram ( ECG ) cardiac ultrasound . Clinical parameter In accordance ESH guideline , BP assessment carry note two measurement supine , sit stand position , space apart 1-2 minute . For current study mean value sit position consider . BP measurement assess trained personnel use dedicate , upper arm , electronic machine ( Afib screen , Microlife , Italy ) Anthropometric parameter . The weight class define BMI [ weight ( kg ) /height ( ) 2 ] . In adult , overweight identify BMI 25-29.9 kg/m2 , obesity BMI≥30 kg/m2 . Biochemical parameter For patient , follow laboratory test evaluate : fasting glucose , total cholesterol , LDL , HDL , triglyceride , blood urea nitrogen ( BUN ) , serum creatinine creatinine clearance ( calculate MDRD Cockroft formula ) . Fasting blood glucose great 126 mg/dl use screen diabetes . Follow-up computerize medical record The patient population include central database use Wincare software ( TSD-Projects , Milan , Italy ) , contain separate electronic sheet medical history , physical examination , laboratory test , electrocardiogram , cardiac ultrasound , image test ambulatory blood pressure monitoring . The data update follow-up visit revaluation deadline set three month . The data patient store hospital server protect firewall system password access . Echocardiography All patient subject one-dimensional echocardiography ( M-mode ) , two-dimensional ( B-mode ) Doppler function via 5-1MHz probe ( E9 , GE Healthcare ) . Statistical analysis Categorical data present percent continuous data indicate mean ± standard error . The quantitative analysis perform use T-test unpaired data ANOVA appropriate , qualitative analysis perform use non-parametric test ( χ2 test ) . A value p-value &lt; 0.05 consider statistically significant . All data analyze use Prism 6.0 ( GraphPad Software , Inc. , San Diego , CA ) .</detailed_description>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Hypertensive patient first diagnosis arterial hypertension absence previous treatment . Patients exclude patient secondary hypertension , malignant hypertension , CRF ( chronic renal failure ) , oncological condition cirrhosis . Patients also exclude patient medical surgical disorder alter absorption , distribution , metabolism excretion drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Combination therapy</keyword>
	<keyword>ACE inhibitor Calcium Antagonist</keyword>
</DOC>